ABOUT US

Our vision is to discover, develop and commercialize antibody-based solutions to address the current COVID-19 pandemic, as well as potential future viral diseases with pandemic potential.

ABOUT US

Our vision is to discover, develop and commercialize antibody-based solutions to address the current COVID-19 pandemic, as well as potential future viral diseases with pandemic potential.

At Adagio, our goal is to develop and commercialize differentiated antibody-based solutions with broadly neutralizing activity for the treatment and prevention of diseases caused by SARS CoV-2, its variants and additional SARS-like viruses with pandemic potential. To enable this, our discovery efforts are focused on broadly neutralizing antibodies that target conserved epitopes across multiple members of the coronavirus family.

We also plan to leverage our robust antibody discovery and development capabilities to develop therapeutic or preventative options for other respiratory viral infections, such as seasonal and pandemic influenza.

We were founded in June 2020 to develop a portfolio of anti-coronavirus antibodies discovered by Adimab for both the treatment and prevention of COVID-19 and future coronavirus outbreaks. Our founding scientists discovered ADG20, our lead product candidate, while working at Adimab, an industry leader in translating target hypotheses into therapeutically relevant antibodies. The Adimab platform has been used in more than 385 antibody discovery and optimization programs, more than 40 of which have advanced into clinical trials, including five programs in pivotal clinical trials.

Management Team

David Hering, M.B.A

David Hering, M.B.A

Chief Executive Officer & Director

Jill Andersen, J.D.

Jill Andersen, J.D.

Chief Legal Officer & Corporate Secretary

Becky Dabora, Ph.D.

Becky Dabora, Ph.D.

Chief Technology & Manufacturing Officer

Jane Pritchett Henderson

Jane Pritchett Henderson

Chief Financial & Business Officer

Ellie Hershberger, Pharm.D.

Ellie Hershberger, Pharm.D.

Chief Development Officer

Eric Kimble, M.B.A.

Eric Kimble, M.B.A.

Chief Commercial Officer

Laura Walker, Ph.D.

Laura Walker, Ph.D.

Co-Founder & Chief Scientific Officer

Board of Directors

Tamsin Berry

Partner, Population Health Partners

Marc Elia

Founder and Chief Investment Officer, M28 Capital Management L.P., Chairperson of the Board

David Hering, M.B.A

Chief Executive Officer & Director

Tom Heyman

Former President, Johnson & Johnson Development Corporation (JJDC)

Terry McGuire

Partner, Polaris Partners

Clive A. Meanwell, M.D.

Executive Chair and Co-founder, Population Health Partners

Redonda Miller, M.D., MBA

President, The Johns Hopkins Hospital

Michael Wyzga

President, MSW Consulting, Inc.